Dow heads for best month since 1976 | Post-midterms rally ahead? | Goldman's picks for the long term

Stocks are set to exit October with a tailwind, as the market enters a historically positive time of year for stocks.

VIEW IN BROWSER | SUBSCRIBE SAT, OCT 29, 2022 WEEKEND BRIEF EDITOR'S NOTE Stocks are set to exit October with a tailwind, as the market enters a historically positive time of year. The Federal Reserve's meeting Tuesday and Wednesday is the key to the week ahead, and the outcome could also help decide how markets will trade for the rest of the year.   The Fed is expected to raise its fed funds target rate by three-quarters of a point, but there is some expectation that Fed Chairman Jerome Powell could signal that the Fed is considering paring back the size of future rate hikes. Stock strategists say that could help keep the rally going.   October has been positive for the market despite the volatility and major declines in some Big Tech names. The Dow, as of Friday, was up 14.4% for the month, its best monthly performance since 1976. Besides the Fed, there is a heavy economic calendar, with Friday's September jobs report the most important report. It is also a very busy week for earnings, with about a third of S&P 500 companies reporting. Patti Domm | CNBC Markets Editor @pattidomm THE WEEK AHEAD The Fed could lay the groundwork for a year-end rally in the week ahead MICHAEL SANTOLI'S MARKET COLUMN The market is moving in-line with seasonal patterns almost perfectly — Post-midterms rally next? ACTIVIST SPOTLIGHT Activist Starboard takes a stake in Vertiv, and an opportunity to boost margins is in sight YOUR WEEKEND BRIEFING  Cramer's week ahead: There could be 'real signs' for the Fed to slow down These five stocks are best positioned for long-term growth, Goldman analysts say GM temporarily suspends advertising on Twitter following Elon Musk takeover These stocks reporting earnings in the week ahead have a track record of beating expectations and trading higher Chrysler and Jeep parent Stellantis offering buyouts to some U.S. salaried employees FDA says two studies showing omicron boosters weren't much better than old Covid shots were too small to come to any conclusions Unsubscribe Manage Newsletters Terms of Service Join the CNBC Panel Digital Products Feedback Privacy Policy © 2022 CNBC LLC. All rights reserved. A property of NBCUniversal. 900 Sylvan Avenue, Englewood Cliffs, NJ 07632 Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis. Data also provided by THOMSON REUTERS